YIDU TECH (02158) announces profit increase, with an expected profit of around 410-560 million yuan for the 2026 fiscal year, turning losses into profits year-on-year.
iMedical Technology (02158) announced that the group expects to achieve a net profit of approximately 55 to 70 million yuan for the fiscal year ending March 31, 2026, while it incurred a net loss of approximately 135 million yuan in the 2025 fiscal year. The expected net profit attributable to owners of the company for the 2026 fiscal year is approximately 41 to 56 million yuan, compared to a net loss of approximately 118 million yuan for the owners of the company in the 2025 fiscal year.
YIDU TECH (02158) announced that the group expects to achieve a net profit of approximately 55-70 million yuan for the financial year ending March 31, 2026, while in the 2025 financial year, it incurred a net loss of approximately 135 million yuan. It is also expected that the group's attributable profit to owners for the 2026 financial year will be around 41-56 million yuan, compared to an attributable loss of approximately 118 million yuan in the 2025 financial year.
The board of directors believes that the expected turnaround from loss to profit is mainly due to (i) the continuous upgrading of the group's products with AI capabilities, resulting in increased new orders in the core business sectors of the group, enhancing the value proposition and competitiveness of the group's products; and (ii) an improvement in gross profit margin, attributed to the higher added value of AI-incorporated products after upgrading, improved operational efficiency, and economies of scale.
Related Articles

Lilly (LLY.US) intends to spend over $2 billion to acquire Kelonia, further expanding its presence in the blood cancer market.

Hong Kong Stock Market Concept Tracking | Price Surges by 650%! Fiber optic industry welcomes surge in both volume and price, high prosperity may continue until the end of 2027 (Attached concept stocks)

ASCENTAGE-B (06855) was showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting, presenting four clinical advancements and demonstrating the potential of combination therapies.
Lilly (LLY.US) intends to spend over $2 billion to acquire Kelonia, further expanding its presence in the blood cancer market.

Hong Kong Stock Market Concept Tracking | Price Surges by 650%! Fiber optic industry welcomes surge in both volume and price, high prosperity may continue until the end of 2027 (Attached concept stocks)

ASCENTAGE-B (06855) was showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting, presenting four clinical advancements and demonstrating the potential of combination therapies.

RECOMMEND

Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026

Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026

Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026


